Abstract
Maintaining efficacy of human immunodeficiency virus (HIV) medications is challenging among children because of dosing difficulties, the limited number of approved drugs, and low rates of medication adherence. Drug level feedback (DLF) can support dose optimization and timely interventions to prevent treatment failure, but current tests are heavily instrumented and centralized. We developed the REverse-transcriptase ACTivity-crispR (REACTR) assay for rapid measurement of HIV drugs based on the extent of DNA synthesis by HIV reverse transcriptase. CRISPR-Cas enzymes bind to synthesized DNA, triggering collateral cleavage of quenched reporters and generating fluorescence. We measured azidothymidine triphosphate (AZT-TP), a key drug in pediatric HIV treatment, and investigated the impact of assay time and DNA template length on REACTR’s sensitivity. REACTR selectively measured clinically relevant AZT-TP concentrations in the presence of genomic DNA and peripheral blood mononuclear cell lysate. REACTR has the potential to enable rapid point-of-care HIV DLF to improve pediatric HIV care.
Competing Interest Statement
M.A.S., M.M.C., Q.W., C.R., B.R.L., and A.O.O. are inventors on a patent filed (63/723495) based on this work. A.O.O. is an inventor on a patent filed (PCT/US2020/037609) based on related work on enzymatic assays for measuring reverse transcriptase inhibitors. B.R.L. holds equity in a startup company that has licensed related technology and supports ongoing work in the B.R.L. laboratory at the University of Washington. B.R.L serves as a scientific advisor for the company. The company played no role in the funding, study design, data analyses, or reporting of results for this study
